Loading…
Taysha Gene Therapies, Inc. is projected to rise to $7.21 by 2027, a +23% move from its current price of $5.88. TSHA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $5.65 | $5.88 | $6.11 | +0.08% |
| Aug 2 | $5.57 | $5.88 | $6.22 | +0.16% |
| Aug 3 | $5.50 | $5.89 | $6.30 | +0.24% |
| Aug 4 | $5.45 | $5.89 | $6.37 | +0.32% |
| Aug 5 | $5.41 | $5.90 | $6.44 | +0.41% |
| Aug 6 | $5.36 | $5.90 | $6.50 | +0.49% |
| Aug 7 | $5.33 | $5.91 | $6.55 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.33 | $5.91 | $6.55 | +0.57% |
| Week 2 | $5.13 | $5.94 | $6.88 | +1.14% |
| Week 3 | $5.00 | $5.98 | $7.15 | +1.71% |
| Week 4 | $4.89 | $6.01 | $7.39 | +2.29% |
| Week 5 | $4.80 | $6.04 | $7.61 | +2.87% |
| Week 6 | $4.72 | $6.08 | $7.83 | +3.45% |
| Week 7 | $4.65 | $6.11 | $8.03 | +4.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies, Inc. (TSHA) operates in the Healthcare sector and trades with a current price of $5.58. The stock has a market capitalization of $1.6B and is ranked 2077 by market cap.
The near-term price outlook shows upside potential, with the 2026 average price aligning with the current level and longer-horizon forecasts implying meaningful upside by 2030 and beyond.
A major floor 30.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 18.1% above — a clean break opens room to run.
A major ceiling 29.8% above — clearing it would confirm fresh momentum.
Key TSHA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TSHA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.60 | Buy | $5.69 | Buy |
| MA 10 | $5.67 | Buy | $5.73 | Buy |
| MA 20 | $5.94 | Sell | $5.86 | Buy |
| MA 50 | $5.94 | Sell | $5.92 | Sell |
| MA 100 | $5.68 | Buy | $5.70 | Buy |
| MA 200 | $5.25 | Buy | $5.14 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.40 | Neutral |
| Stoch RSI (14) | 95.47 | Sell |
| CCI (20) | -11.99 | Neutral |
| Williams %R (14) | -38.89 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | 3.07 | Buy |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 61.11 | Neutral |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -0.50 | Sell |
| Ultimate (7,14,28) | 53.29 | Neutral |
| Momentum (10) | -0.09 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 5.59 | Buy |
| ADX (14) | 12.54 | Neutral |
| ATR (14) | 0.20 | Info |
Key near-term technicals show a cautious setup. The RSI(14) is 40, and the stock trades around the SMA200 at $5.21 and the SMA50 at $6.07, indicating a blend of support near the longer-term moving average and overhead pressure toward the shorter-term average. A clear support level is noted at $5.36, with resistance at $6.94.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.07 | $5.88 | $8.36 | 0% | Neutral | |
| $5.53 | $7.21 | $10.08 | +23% | Bullish | |
| $5.24 | $7.14 | $10.49 | +21% | Bullish | |
| $7.03 | $9.92 | $15.16 | +69% | Bullish | |
| $9.08 | $13.22 | $20.87 | +125% | Bullish | |
| $9.99 | $14.98 | $24.32 | +155% | Bullish | |
| $11.07 | $17.05 | $28.38 | +190% | Bullish | |
| $11.11 | $17.55 | $29.88 | +199% | Bullish | |
| $11.65 | $18.87 | $32.79 | +221% | Bullish | |
| $12.47 | $20.69 | $36.64 | +252% | Bullish | |
| $18.75 | $34.77 | $66.62 | +492% | Bullish | |
| $42.19 | $93.77 | $201.02 | +15.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.07 | $5.88 | $6.86 | +0.00% |
| August 2026 | $5.05 | $5.98 | $7.29 | +1.77% |
| September 2026 | $5.28 | $6.32 | $7.85 | +5.78% |
| October 2026 | $5.27 | $6.38 | $8.04 | +0.86% |
| November 2026 | $5.15 | $6.28 | $8.01 | -1.49% |
| December 2026 | $5.27 | $6.48 | $8.36 | +3.15% |
Click any year to see its month-by-month TSHA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TSHA could reach as high as $8.36, with a base case around $5.88 and support toward $4.07 — roughly 0% from $5.88. A consolidation phase looks the most probable path here.
Expect TSHA to range from $5.53 to $10.08 through 2027. The $7.21 average target implies a +23% move from current prices. That is up +23% on the projected 2026 average. Momentum favours further upside here.
The TSHA price prediction for 2028 points to an average of $7.14 (low $5.24, high $10.49) — a potential gain of +21% on today's $5.88. Buyers look set to stay in control over this stretch.
In 2029, TSHA is projected to trade between $7.03 and $15.16, averaging $9.92 — a potential gain of +69% from today's $5.88. That is up +39% on the projected 2028 average. Momentum favours further upside here.
Taysha Gene Therapies, Inc.'s 2030 outlook centres on $13.22, within a $9.08 to $20.87 range. That is up +33% on the projected 2029 average. That marks a +125% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, TSHA could reach as high as $24.32, with a base case around $14.98 and support toward $9.99 — roughly +155% from $5.88. Momentum favours further upside here.
Expect TSHA to range from $11.07 to $28.38 through 2032. The $17.05 average target implies a +190% move from current prices. That is up +14% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The TSHA price prediction for 2033 points to an average of $17.55 (low $11.11, high $29.88) — a potential gain of +199% on today's $5.88. Momentum favours further upside here.
In 2034, TSHA is projected to trade between $11.65 and $32.79, averaging $18.87 — a potential gain of +221% from today's $5.88. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Taysha Gene Therapies, Inc.'s 2035 outlook centres on $20.69, within a $12.47 to $36.64 range. That is up +10% on the projected 2034 average. That marks a +252% change versus current levels. Momentum favours further upside here.
By 2040, TSHA could reach as high as $66.62, with a base case around $34.77 and support toward $18.75 — roughly +492% from $5.88. Buyers look set to stay in control over this stretch.
Expect TSHA to range from $42.19 to $201.02 through 2050. The $93.77 average target implies a +15.0x move from current prices. That is up +170% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in TSHA today (≈ 170.212766 TSHA) could be worth
$15,960.04
+$14,960.04 (+1496%) by 2050 · US Dollar
Based on the average projected TSHA price of $93.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TSHAwould be worth at today's price.
$1,000 invested in TSHA on Jul 30, 2025 (≈ 364.963502 TSHA) would be worth
$2,144.16
+$1,144.16 (+114.4%) today · 2.14× · US Dollar
Based on a TSHA entry price of $2.74 vs. today's $5.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.83 | $1,007.72 | +0.8% |
| 1 month ago | $6.81 | $862.7 | -13.7% |
| 3 months ago | $6.33 | $928.12 | -7.2% |
| 6 months ago | $4.51 | $1,302.66 | +30.3% |
| 1 year ago | $2.74 | $2,144.16 | +114.4% |
| All time (5.0y) ago | $17.95 | $327.3 | -67.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TSHA forecast.
Our base-case forecast reaches $12.00 around 2030.
Implied market cap at $12.00: $3.45B
The multi-year forecast depicts a clear upside trajectory, with the 2026 average price of $5.58 and a bullish tilt developing from 2029 onward. By 2030, the forecast shows an avg of $11.29 with a max of $18.64 and a min of $7.39, delivering a 102.3% ROI. The outlook remains bullish in 2031–2035 and through 2040, with 2040’s average price at $26.59 and a max of $54.38 (ROI 376.4%).
By 2050, the avg price is projected at $71.41 with a max of $164.25 and a Return on Investment of 1179.8% (ROI). Sentiment turns bullish from 2029 onward, reflecting sustained upside potential, though these are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030, the average forecast price is $11.29, with a min of $7.39 and a max of $18.64, and a ROI of 102.3%. The forecast also shows a bullish sentiment for that year.
Forecasts indicate bullish sentiment from 2029 onward, with the 2030 average at $11.29 and the 2050 average at $71.41, corresponding to a ROI of 102.3% in 2030 and 1179.8% in 2050. These are estimates and not guarantees.
Yes—the forecast max price for 2040 is $54.38.
Current price is $5.58 and market cap is $1.6B.
RSI(14) is 40, SMA50 is $6.07, SMA200 is $5.21. Support is at $5.36 and resistance at $6.94. The 30-day range is $4.13 to $7.54 and annualized volatility is 90%.
Taysha Gene Therapies, Inc. Community Discussion
0Share your Taysha Gene Therapies, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.